The global generic injectable market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing demand for generic injectables in emerging economies such as India and China. The increasing number of patients suffering from chronic diseases such as diabetes and cancer are also driving the growth of this market.
The North American region is expected to dominate the global generic injectable market during the forecast period, due to its high prevalence rates for chronic diseases such as diabetes and cancer, which are driving demand for these products in this region.
Some Of The Growth Factors Of This Market:
- Increasing prevalence of chronic diseases such as diabetes and cancer is driving the growth of the Generic Sterile Injectable market globally.
- Increasing number of hospitalizations due to chronic diseases is also driving the growth of the Generic Sterile Injectable market globally.
- Increasing geriatric population in developing countries such as China and India is also driving the growth of the Generic Sterile Injectable market globally, as these countries have a large population aged 65 years or more which are prone to chronic diseases such as diabetes and cancer which require treatment with injectables on a regular basis for prolonged periods, thus increasing demand for generic sterile injectables in these regions over time .
Industry Growth Insights published a new data on “Generic Sterile Injectable Market”. The research report is titled “Generic Sterile Injectable Market research by Types (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines, Others), By Applications (Hospitals, Pharmacies, Online Pharmacies), By Players/Companies 3M, Baxter Inc, Fresenius Kabi, Pfizer/Hospira, Novartis/Sandoz, Teva, Hikma, Sun Pharma, Dr. Reddy’s, Mylan, AstraZeneca Plc, Merck & Co., Inc, Hellberg Safety Ab”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Generic Sterile Injectable Market Research Report
By Type
Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines, Others
By Application
Hospitals, Pharmacies, Online Pharmacies
By Companies
3M, Baxter Inc, Fresenius Kabi, Pfizer/Hospira, Novartis/Sandoz, Teva, Hikma, Sun Pharma, Dr. Reddy’s, Mylan, AstraZeneca Plc, Merck & Co., Inc, Hellberg Safety Ab
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Generic Sterile Injectable Market Report Segments:
The global Generic Sterile Injectable market is segmented on the basis of:
Types
Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- 3M
- Baxter Inc
- Fresenius Kabi
- Pfizer/Hospira
- Novartis/Sandoz
- Teva
- Hikma
- Sun Pharma
- Dr. Reddy’s
- Mylan
- AstraZeneca Plc
- Merck & Co., Inc
- Hellberg Safety Ab
Highlights of The Generic Sterile Injectable Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies
- Cytokines
- Insulin
- Peptide Hormones
- Vaccines
- Others
- By Application:
- Hospitals
- Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Generic Sterile Injectable Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Generic sterile injectable is a medication that is designed to be used in place of a brand name medication. It has the same active ingredients and effects as the brand name medication, but it is not made by the original manufacturer.
Some of the major players in the generic sterile injectable market are 3M, Baxter Inc, Fresenius Kabi, Pfizer/Hospira, Novartis/Sandoz, Teva, Hikma, Sun Pharma, Dr. Reddy¢â‚¬â„¢s, Mylan, AstraZeneca Plc, Merck & Co., Inc, Hellberg Safety Ab.
The generic sterile injectable market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Generic Sterile Injectable Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Generic Sterile Injectable Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Generic Sterile Injectable Market - Supply Chain
4.5. Global Generic Sterile Injectable Market Forecast
4.5.1. Generic Sterile Injectable Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Generic Sterile Injectable Market Size (000 Units) and Y-o-Y Growth
4.5.3. Generic Sterile Injectable Market Absolute $ Opportunity
5. Global Generic Sterile Injectable Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Generic Sterile Injectable Market Size and Volume Forecast by Type
5.3.1. Monoclonal Antibodies
5.3.2. Cytokines
5.3.3. Insulin
5.3.4. Peptide Hormones
5.3.5. Vaccines
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Generic Sterile Injectable Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Generic Sterile Injectable Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Generic Sterile Injectable Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Generic Sterile Injectable Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Generic Sterile Injectable Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Generic Sterile Injectable Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Generic Sterile Injectable Demand Share Forecast, 2019-2026
9. North America Generic Sterile Injectable Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Generic Sterile Injectable Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Generic Sterile Injectable Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Generic Sterile Injectable Market Size and Volume Forecast by Type
9.7.1. Monoclonal Antibodies
9.7.2. Cytokines
9.7.3. Insulin
9.7.4. Peptide Hormones
9.7.5. Vaccines
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Generic Sterile Injectable Demand Share Forecast, 2019-2026
10. Latin America Generic Sterile Injectable Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Generic Sterile Injectable Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Generic Sterile Injectable Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Generic Sterile Injectable Market Size and Volume Forecast by Type
10.7.1. Monoclonal Antibodies
10.7.2. Cytokines
10.7.3. Insulin
10.7.4. Peptide Hormones
10.7.5. Vaccines
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Generic Sterile Injectable Demand Share Forecast, 2019-2026
11. Europe Generic Sterile Injectable Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Generic Sterile Injectable Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Generic Sterile Injectable Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Generic Sterile Injectable Market Size and Volume Forecast by Type
11.7.1. Monoclonal Antibodies
11.7.2. Cytokines
11.7.3. Insulin
11.7.4. Peptide Hormons
11.7.5. Vaccines
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Generic Sterile Injectable Demand Share, 2019-2026
12. Asia Pacific Generic Sterile Injectable Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Generic Sterile Injectable Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Generic Sterile Injectable Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Generic Sterile Injectable Market Size and Volume Forecast by Type
12.7.1. Monoclonal Antibodies
12.7.2. Cytokines
12.7.3. Insulin
12.7.4. Peptide Hormones
12.7.5. Vaccines
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Generic Sterile Injectable Demand Share, 2019-2026
13. Middle East & Africa Generic Sterile Injectable Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Generic Sterile Injectable Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Generic Sterile Injectable Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Generic Sterile Injectable Market Size and Volume Forecast by Type
13.7.1. Monoclonal Antibodies
13.7.2. Cytokines
13.7.3. Insulin
13.7.4. Peptide Hormones
13.7.5. Vaccines
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Generic Sterile Injectable Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Generic Sterile Injectable Market: Market Share Analysis
14.2. Generic Sterile Injectable Distributors and Customers
14.3. Generic Sterile Injectable Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. 3M
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Baxter Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Fresenius Kabi
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer/Hospira
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novartis/Sandoz
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Teva
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Hikma
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Sun Pharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Dr. Reddys
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Mylan
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. AstraZeneca Plc
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Merck & Co., Inc
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Hellberg Safety Ab
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
